Michael Kennis
Sylvania, OHNPI 1215291083
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. AbbVie accounts for 97.7% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $58,188, more than ten times the $247 reported in 2020.
Across 245 payments — averaging $458.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$110K
- Merz North America, Inc.$2K
- Galderma Laboratories, L.p.$530
- Abbott$109
What the payments were for
- Consulting fees$42,06937%
- Speaking & faculty fees$53,96148%
- Travel & lodging$6,7286%
- Food & beverage$9,4948%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 216 | $109,694 |
| Merz North America, Inc. | 21 | $1,967 |
| Galderma Laboratories, L.p. | 7 | $530 |
| Abbott | 1 | $109 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$57,320
- XEOMIN$1,223
- ID NOW INSTRUMENT$109
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.